Skip to main content
Erschienen in: Surgery Today 9/2021

07.04.2021 | Original Article

Predictive scoring system for advanced liver fibrosis in Japanese patients with severe obesity

verfasst von: Haruka Nikai, Akira Sasaki, Akira Umemura, Naoto Takahashi, Hiroyuki Nitta, Risaburo Akasaka, Keisuke Kakisaka, Hidekatsu Kuroda, Kazuyuki Ishida, Yasuhiro Takikawa

Erschienen in: Surgery Today | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to examine the predictive scoring system of advanced liver fibrosis in severely obese Japanese patients.

Methods

Seventy-two patients underwent laparoscopic sleeve gastrectomy and intraoperative liver biopsies. We classified these patients into two groups: Brunt stage ≥ 2 (advanced fibrosis) and 0/1 (none/mild fibrosis). A logistic regression analysis was performed to identify the predictors of advanced fibrosis.

Results

Sixteen patients had advanced fibrosis, while 56 had no/mild fibrosis. The prevalence of type 2 diabetes mellitus (T2DM) in advanced fibrosis group was significantly higher than in none/mild fibrosis. An univariate analysis of the factors predicting advanced fibrosis showed significant differences in AST/ALT ratio, serum insulin levels, HOMA-IR, and type IV collagen 7S in the T2DM group. According to a multivariate analysis, type IV collagen 7S was an independent predictor and the cutoff value was 5.6 ng/mL. We created a flow chart; high risk (T2DM and type IV collagen 7S ≥ 5.6 ng/mL), moderate risk (T2DM and type IV collagen 7S < 5.6 ng/mL), and low risk (non-DM). For those at high risk, the sensitivity, specificity, positive predictive value, and negative predictive value were 56.2%, 94.4%, 75.0%, and 87.9%, respectively.

Conclusion

This classification system has the potential to accurately categorize the risk of liver fibrosis.
Literatur
1.
Zurück zum Zitat Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2005;11:255–9.CrossRef Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2005;11:255–9.CrossRef
2.
Zurück zum Zitat Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586–95.CrossRef Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586–95.CrossRef
3.
Zurück zum Zitat Cummings DE, Cohen RV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol. 2014;2:175–81.CrossRef Cummings DE, Cohen RV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol. 2014;2:175–81.CrossRef
4.
Zurück zum Zitat Ohta M, Seki Y, Wong SK, Wang C, Huang C, Aly A, et al. Bariatric/metabolic surgery in the Asia-Pacific region: APMBSS survey. Obes Surg. 2018;29:534–41.CrossRef Ohta M, Seki Y, Wong SK, Wang C, Huang C, Aly A, et al. Bariatric/metabolic surgery in the Asia-Pacific region: APMBSS survey. Obes Surg. 2018;29:534–41.CrossRef
5.
Zurück zum Zitat Bower G, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25:2280–9.CrossRef Bower G, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25:2280–9.CrossRef
6.
Zurück zum Zitat Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–88.CrossRef Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–88.CrossRef
7.
Zurück zum Zitat Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, et al. Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments. Front Endoscorinol (Lausanne). 2014;5:164. Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, et al. Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments. Front Endoscorinol (Lausanne). 2014;5:164.
8.
Zurück zum Zitat Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–65.CrossRef Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–65.CrossRef
9.
Zurück zum Zitat Loomba R. The hierarchical model of NAFLD: prognostic significance of histologic features in NASH. Gastroenterology. 2015;149:278–80.CrossRef Loomba R. The hierarchical model of NAFLD: prognostic significance of histologic features in NASH. Gastroenterology. 2015;149:278–80.CrossRef
10.
Zurück zum Zitat Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatrol. 2009;7:1004–112. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatrol. 2009;7:1004–112.
11.
Zurück zum Zitat Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.CrossRef Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.CrossRef
12.
Zurück zum Zitat Kao WY, Chang IW, Chen CL, Su CW, Fang SU, Tang JH, et al. Fibroscan-based score to predict significant liver fibrosis in mobidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2020;30(4):1249–57.CrossRef Kao WY, Chang IW, Chen CL, Su CW, Fang SU, Tang JH, et al. Fibroscan-based score to predict significant liver fibrosis in mobidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2020;30(4):1249–57.CrossRef
13.
Zurück zum Zitat Okanoue T, Ebise H, Kai T, Mizuno M, Shima T, Ichihara J, et al. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. J Gastroenterol. 2018;53:129–39.CrossRef Okanoue T, Ebise H, Kai T, Mizuno M, Shima T, Ichihara J, et al. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. J Gastroenterol. 2018;53:129–39.CrossRef
14.
Zurück zum Zitat Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRef Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRef
15.
Zurück zum Zitat Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Teri BA, Bacon BR, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRef Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Teri BA, Bacon BR, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRef
16.
Zurück zum Zitat Sakamoto M, Tsujikawa H, Effendi K, Ojima H, Harada K, Zen Y, et al. Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Pathol Int. 2017;67:1–7.CrossRef Sakamoto M, Tsujikawa H, Effendi K, Ojima H, Harada K, Zen Y, et al. Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Pathol Int. 2017;67:1–7.CrossRef
17.
Zurück zum Zitat Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 1999;118:1117–23.CrossRef Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 1999;118:1117–23.CrossRef
18.
Zurück zum Zitat Seki Y, Kakizaki S, Horiguchi N, Hashizume H, Tojima H, Yamazaki Y, et al. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery. J Gastroenterol. 2016;51:281–9.CrossRef Seki Y, Kakizaki S, Horiguchi N, Hashizume H, Tojima H, Yamazaki Y, et al. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery. J Gastroenterol. 2016;51:281–9.CrossRef
19.
Zurück zum Zitat Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239:105–12.CrossRef Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239:105–12.CrossRef
20.
Zurück zum Zitat Rogier J, Roullet S, Cornelis F, Biais M, Quinart A, Revel P, et al. Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio. Liver Transpl. 2015;21:690–5.CrossRef Rogier J, Roullet S, Cornelis F, Biais M, Quinart A, Revel P, et al. Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio. Liver Transpl. 2015;21:690–5.CrossRef
21.
Zurück zum Zitat Endo Y, Ohta M, Tada K, Nakanuma H, Saga K, Masuda T, et al. Improvement of non-alcoholic fatty liver disease after laparoscopic sleeve gastrectomy in Japanese obese patients. Ann Gastroenterol Surg. 2019;3:285–90.CrossRef Endo Y, Ohta M, Tada K, Nakanuma H, Saga K, Masuda T, et al. Improvement of non-alcoholic fatty liver disease after laparoscopic sleeve gastrectomy in Japanese obese patients. Ann Gastroenterol Surg. 2019;3:285–90.CrossRef
22.
Zurück zum Zitat Nikai H, Ishida K, Umemura A, Baba S, Nitta H, Sugai T, et al. Effects of laparoscopic sleeve gastrectomy on non-alcoholic steatohepatitis and liver fibrosis in japanese patients with severe obesity. Obes Surg. 2020;30(7):2579–87.CrossRef Nikai H, Ishida K, Umemura A, Baba S, Nitta H, Sugai T, et al. Effects of laparoscopic sleeve gastrectomy on non-alcoholic steatohepatitis and liver fibrosis in japanese patients with severe obesity. Obes Surg. 2020;30(7):2579–87.CrossRef
23.
Zurück zum Zitat Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.CrossRef Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.CrossRef
24.
Zurück zum Zitat Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010;10:67.CrossRef Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010;10:67.CrossRef
25.
Zurück zum Zitat Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut. 2009;58:1566–7.CrossRef Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut. 2009;58:1566–7.CrossRef
26.
Zurück zum Zitat Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11:137–41.CrossRef Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11:137–41.CrossRef
27.
Zurück zum Zitat Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12:491–502.CrossRef Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12:491–502.CrossRef
28.
Zurück zum Zitat Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB-4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.CrossRef Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB-4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.CrossRef
29.
Zurück zum Zitat Kim M, Jun DW, Park H, Kang BK, Sumida Y. Sequential combination of FIB-4 followed by M2BPGi enhanced diagnostic performance for advanced hepatic fibrosis in an average risk population. J Clin Med. 2020;9:1119.CrossRef Kim M, Jun DW, Park H, Kang BK, Sumida Y. Sequential combination of FIB-4 followed by M2BPGi enhanced diagnostic performance for advanced hepatic fibrosis in an average risk population. J Clin Med. 2020;9:1119.CrossRef
30.
Zurück zum Zitat Nakahara T, Hyogo H, Yoeda M, Sumida Y, Eguchi Y, Fujii H, Japan Study Group of Nonalcoholic Fatty Liver Disease, et al. Type 2 diabetes mellitus associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49:1477–84.CrossRef Nakahara T, Hyogo H, Yoeda M, Sumida Y, Eguchi Y, Fujii H, Japan Study Group of Nonalcoholic Fatty Liver Disease, et al. Type 2 diabetes mellitus associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49:1477–84.CrossRef
31.
Zurück zum Zitat Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, et al. Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. Hepatol Res. 2015;45:548–59.CrossRef Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, et al. Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. Hepatol Res. 2015;45:548–59.CrossRef
32.
Zurück zum Zitat Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17:95.CrossRef Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17:95.CrossRef
33.
Zurück zum Zitat Yoeda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, et al. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol. 2007;42:375–81.CrossRef Yoeda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, et al. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol. 2007;42:375–81.CrossRef
34.
Zurück zum Zitat Mizuno M, Shima T, Oya H, Mitsumoto Y, Mizuno C, Isoda S, et al. Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers. Hepatol Res. 2016;47:216–25.CrossRef Mizuno M, Shima T, Oya H, Mitsumoto Y, Mizuno C, Isoda S, et al. Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers. Hepatol Res. 2016;47:216–25.CrossRef
35.
Zurück zum Zitat Brandon H, Martin W. Protein homeostasis: live long, won’t prosper. Nat Rev Mol Cell Biol. 2013;14:55–61.CrossRef Brandon H, Martin W. Protein homeostasis: live long, won’t prosper. Nat Rev Mol Cell Biol. 2013;14:55–61.CrossRef
Metadaten
Titel
Predictive scoring system for advanced liver fibrosis in Japanese patients with severe obesity
verfasst von
Haruka Nikai
Akira Sasaki
Akira Umemura
Naoto Takahashi
Hiroyuki Nitta
Risaburo Akasaka
Keisuke Kakisaka
Hidekatsu Kuroda
Kazuyuki Ishida
Yasuhiro Takikawa
Publikationsdatum
07.04.2021
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 9/2021
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-021-02266-w

Weitere Artikel der Ausgabe 9/2021

Surgery Today 9/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.